Skip to content
MarketScale
‹ Back to IndustriesHealthcare

AI’s Advances in Healthcare Can Save Lives and Money

In recent years, artificial intelligence (AI) technology has emerged as a sort of boogeyman in countless fields. While prominent voices promise that AI will kill jobs across the board, AI has been quietly and effectively becoming an integral part of the healthcare system. The US healthcare system is in crisis, and AI seems to have…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

In recent years, artificial intelligence (AI) technology has emerged as a sort of boogeyman in countless fields. While prominent voices promise that AI will kill jobs across the board, AI has been quietly and effectively becoming an integral part of the healthcare system. The US healthcare system is in crisis, and AI seems to have some life saving answers. Let’s explore these issues, AI’s role in healthcare, and expectations for the years to come.

It’s no secret that the United States healthcare industry faces numerous challenges. From mounting costs, increasing drug-resistance, overtreatment, and a failure to adopt preventative practices, at nearly every turn there’s a major roadblock to care.[1] Fortunately, the Health Information Technology for Economic and Clinical Health (HITECH) Act, has created a large database of electronic health records. AI’s access to that data has allowed for the development of predictive models and even real-time diagnoses, treatment protocol, personalized medicine, and patient monitoring. But there’s more.

With costs soaring, both physicians and patients are more willing to use self-care kiosks or at-home tests for common illnesses like strep throat.[2] These advances are cyclical, as the more information AI has access to, and the better its processing power becomes, the more effective its treatment is. The bottom line, aside from saving lives, is that some report big data saving medicine and pharmaceuticals nearly $100 billion annually.[3] That’s not something many facilities can afford to ignore.

[1]

https://www.cs.cmu.edu/~neill/papers/ieee-is2013.pdf

[2]

http://usblogs.pwc.com/emerging-technology/ai-in-healthcare/

[3]

https://www.forbes.com/sites/bernardmarr/2017/10/09/the-amazing-ways-how-artificial-intelligence-and-machine-learning-is-used-in-healthcare/#56e12afd1c80

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly is investing $6.5 billion in a Houston manufacturing facility set to open around 2030, primarily to scale production of Foundayo, its oral GLP-1 treatment. The project signals a broader shift in U.S. pharmaceutical manufacturing reshoring and underscores the supply chain challenge of forecasting demand and building capacity years in advance for breakthrough therapeutics.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

July partnerships show hospitals aligning without ownership change

July partnerships show hospitals aligning without ownership change

A July McDermott Will & Schulte analysis and four July partnership announcements tracked by Becker’s Hospital Review point to affiliation models that stop short of mergers. St. Christopher’s signed a nonbinding letter of intent with Nemours, Jefferson and Temple; Palomar UC San Diego Health began operating July 1 under a joint powers authority. Several announcements explicitly rule out ownership change, shifting the work to contracts covering governance and other terms.

  • 01In an alliance, the contract does the integrating that an org chart does in a merger: McDermott Will & Schulte says governance design, exclusivity, antitrust review, community commitments and exit rights all have to be settled before signing.
  • 02Purchasing is now explicitly on the table in at least one no-ownership deal, the St. Peter's Health and Billings Clinic-Logan Health talks in Montana, which means shared supply contracts can arrive without a change of control.

Sep 19, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512